spacer
home > epc > Autumn 2014
PUBLICATIONS

European Pharmaceutical Contractor

epc
Autumn 2014

   
Text
PDF
bullet
Business and Finance
Clinical Procurement

Under the Hammer


The number of firms engaging in reverse auctions when procuring strategic services is on the rise. This can damage the buyer as well as the supplier, argue Julia Forjanic Klapproth and Douglas Fiebig at Trilogy Writing and Consulting.
 
view
download pdf
bullet
Marketplace & Business
Intellectual Property

Enhancing Assets


Jackie Maguire of Coller IP contends that businesses could be doing more to fully utilise their intellectual property portfolios. To accommodate the pressures of change and get the most out of assets, companies should plan ahead and engage outside help.


 
view
download pdf
bullet
Clinical Trials: Patient Recruitment & Retention
Social Media

Get Connected


The Medical Research Network's Graham Wylie assures us that the major concerns in using social media in clinical trials are all relatively easy to address, as well as discussing the advantages of utilising such tools – many of which are only just being realised by pharma.
 
view
download pdf
bullet
Legal & Regulatory
Proposed EU Data Protection Regulation

Potential Impact


This year, the European Parliament put forward a new regulation on data protection. Samantha Regenthal of Regenthal Legal & Compliance outlines the impact the legislation could have on the industry if implemented.

 
view
download pdf
bullet
Electronic Solutions
Clinical Trial Innovations

Tech Trends


Drug makers are putting increasing pressure on CROs to conduct clinical trials in more innovative ways. David Blackman at PPD advises that new technologies will not only aid partners in providing a higher quality service, but also add value and efficiency to their own business.

 
view
download pdf
bullet
Clinical Research
Patient Safety

Narratives Reporting Events


Patient safety narratives play an important part in any clinical trial, but are often complex, consuming time and money. Despite this – and in order to ensure transparency and consistency – all guidelines and process steps should be adhered to, says Quanticate’s Yvonne Moores.
 
view
download pdf
bullet
Science & Innovation: Cancer Focus
Phase 1 Oncology Trials

Lessons Learned


New challenges are arising with the growing number and size of Phase 1 oncology trials. Sean Hart at Vector Oncology and Rabinder Buttar at ClinTec International share the best ways to optimise study outcomes.
 
view
Lung Cancer Treatment

Nano Debate: Part 1

Shelley Bowers from Asons Solicitors debates the pros and cons of using nanotechnology in the treatment of non-small cell lung cancer. Although the tool holds much hope for the future, it should be approached with caution as it lacks thorough research.
 
view
download pdf
bullet
Therapeutic Innovation
Ageing Populations

Beyond a Single Pill


Capsugel’s Sven Stegemann describes why a ‘one-size-fits-all’ approach to drug design is no longer sufficient in the treatment of diseases of ageing. Various patient-centric products should be explored – and are sometimes essential to adherence in elderly populations.
 
view
download pdf
bullet
Data Management & IT Solutions
Cloud-Based Compliance Software

Secure Environment


Constantly validated, secure data can be achieved through cloud-based compliance systems. However, several myths surround their implementation – James Brown of Zinc Ahead explains why these can be cast aside.
 
view
download pdf
bullet
LABS & Logistics
Laboratory Relocation

The Right Move


Potential research disruption, damage to samples and heavy costs can strike fear into any company considering a laboratory move. John Best at Andrew Porter Ltd tells us how to make a success of any relocation.
 
view
download pdf
bullet
Review
In Conclusion

Breaking News


Graham Hughes
reviews pharma's recent news items, and suggests that the industry is receiving selective press attention.

 
view
download pdf
bullet
Regional Focus
Russia Focus: Risk-Based Monitoring

Instant Results


While there are huge cost savings to be had from implementing risk-based monitoring, the benefits can take years to surface. Synergy Research Group’s Igor Stefanov and John Barker offer Russia as a solution to those looking for quicker rewards.
 
view
download pdf

Research and Development
Diseases of Ageing

Finding the Trigger


Ciriaco Maraschiello at Harlan Contract Research Services believes that, in order to produce more efficacious treatments for age-related conditions, the triggering mechanisms of these diseases need to be fully understood.

 
view
download pdf

Interview
Industry Interview

Gaining Access


Hunter Walker at Atlantic Research Group discusses accessing and utilising sponsors’ biggest asset – and why today’s pharma industry calls for better analytics and data management.
 
view
download pdf
Industry Interview

Maximum Protection


Neil Coulson at Baker Botts discusses the recent difficulties and developments in the intellectual property field, and advises on how pharma can maintain value.

 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase AirBridgeCargo Airlines (ABC), one of the leaders in transportation of pharmaceutical products by air, and Zurich-based cold-chain ULD manufacturer SkyCell have sealed their partnership for the lease of all types of SkyCell containers to meet the demand for evolving volumes of passive pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019 YOY and demonstrated a two-fold increase.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement